Bextra gets the boot from the FDA.
The latest in a line of popular pain medications under investigation because of a link to heart attack and stroke. So, with Bextra unavailable now, Celebrex, becomes the only Cox-2 pain reliever left on the market.
But the FDA also asked that Celebrex be labeled with the strongest safety warning on the market. The warning will highlight the potential for an increased risk of cardiovascular trouble and gastrointestinal bleeding. Cardiologist Dr. Steven Nissen of the Cleveland Clinic was a member of the advisory panel that recommended this to the FDA six weeks ago.
"The FDA moved very quickly, very decisively, and I applaud the decision. They really did follow our recommendations. They are really taking this safety issue seriously and really trying to protect the public health," says Dr. Nissen.
Scientists began investigating Cox-2 drugs when Merck, the maker of Vioxx, voluntarily pulled that drug off the market last September citing heart risks.